Jaguar Health (JAGX) Company Report

Jaguar Health, Inc. entered into Global Amendment #3 agreements on November 17, 2025, with Iliad Research and Trading, L.P., Uptown Capital, LLC, and Streeterville Capital, LLC, amending their respective royalty interests.
Under these amendments, effective April 1, 2026, the monthly royalty payment for each investor will be the greater of $750,000.00 or the actual royalty payment amount.
The company also extended the maturity date of a secured promissory note with Streeterville Capital, LLC to April 1, 2026. This note had an original principal amount of $6,220,812.50.
On November 17, 2025, Jaguar Health, Inc. completed an exchange transaction with Streeterville Capital, LLC, issuing 361,271 shares of common stock in exchange for 25 outstanding shares of Series M Preferred Stock, which were subsequently cancelled and retired.

Nov 19, 2025, 6:36 PM

8-K

Jaguar Health Reports Q3 2025 Financials and Progress on Key Development Programs

JAGX

Earnings

New Projects/Investments

Guidance Update

Jaguar Health reported Q3 2025 combined net revenue of approximately $3.1 million, an increase of 4% over Q2 2025, and equal to Q3 2024. The company's net loss attributable to common shareholders decreased to $9.5 million in Q3 2025 from $9.9 million in Q3 2024. Non-GAAP recurring EBITDA for Q3 2025 was a net loss of $8.9 million, an improvement from a net loss of $9.2 million in Q3 2024.
The company's strategy focuses on negotiating business development partnerships for its late-stage human and animal health products to generate non-dilutive funding.
Key development initiatives include crofelemer for orphan indications such as microvillus inclusion disease (MVID) and short bowel syndrome (SBS), a planned label extension for Mytesi for cancer therapy-related diarrhea (CTD), and the animal health product Canalivia for general diarrhea in dogs.
Jaguar anticipates potential expedited review for crofelemer in intestinal failure by the end of 2026 and aims to complete the randomized withdrawal trial for cancer therapy-related diarrhea by the end of 2026. An animal health partnership is expected to close in the very near future.

Nov 17, 2025, 1:30 PM

Transcript

Jaguar Health Reports Q3 2025 Financials and Provides Pipeline Updates

JAGX

Earnings

New Projects/Investments

Jaguar Health reported combined net revenue of approximately $3.1 million for Q3 2025, which is a 4% increase compared to Q2 2025 and equal to Q3 2024 revenue.
The company's loss from operations was $7.3 million in Q3 2025, a slight increase from $7.2 million in Q3 2024, while net loss attributable to common shareholders decreased to $9.5 million from $9.9 million over the same period.
Jaguar is actively negotiating three key late-stage business development partnerships for Crofelemer, aiming to generate non-dilutive funding for orphan indications (MVID/SBS), cancer therapy-related diarrhea (CTD), and the animal health product Canalivia.
Key milestones include potential expedited review for Crofelemer in MVID/SBS by the end of 2026 and completion of a randomized withdrawal trial for CTD by the end of 2026.

Nov 17, 2025, 1:30 PM

Transcript

Jaguar Health, Inc. Secures Promissory Note

JAGX

Debt Issuance

Jaguar Health, Inc. (JAGX) entered into a Secured Promissory Note with Streeterville Capital, LLC on November 12, 2025, for an original principal amount of $10,810,000.00.
The note carries an 8.00% per annum interest rate and includes an original issue discount of $800,000.00. The lender paid a Purchase Price of $10,000,000.00, with $2,000,000.00 disbursed to the Company and $8,000,000.00 deposited into an account for its wholly-owned subsidiary, JAGX Holdings, LLC (JAGX Sub).
The Company's obligations under the note are secured by a pledge of 100% of the membership interests in JAGX Sub and the $8,000,000.00 held in the Deposit Account.
The note matures 36 months after the Purchase Price Date, and the Lender has the right to redeem up to $600,000.00 plus accrued interest per month starting 12 months after the issuance date.
The agreement includes covenants such as mandatory prepayments for IP Transactions and restrictions on granting security interests or selling equity in JAGX Sub without the Lender's prior written consent.

Nov 14, 2025, 9:31 PM

8-K

Jaguar Health Enters Securities Purchase Agreement for Private Placement

JAGX

Jaguar Health, Inc. entered into a Securities Purchase Agreement with Brown Stone Capital Limited on September 28, 2025, for a private placement.
The company agreed to sell 161,583 Common Shares at $1.56 per share and 479,442 Pre-Funded Warrants (at $1.56 minus $0.0001 per warrant) for a total purchase price of $1,000,000.
Proceeds from this private placement will be used for working capital, general corporate purposes, and the repayment of existing convertible notes.
Jaguar Health, Inc. committed to filing a registration statement on Form S-3 by October 9, 2025, to register the resale of the shares and pre-funded warrant shares.

Oct 1, 2025, 8:15 PM

8-K

Jaguar Health Provides Update on Crofelemer Development Programs and Market Opportunities

JAGX

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Jaguar Health is advancing crofelemer for human cancer therapy-related diarrhea, having filed an orphan drug application for metastatic breast cancer and expecting to complete a treatment trial in 2026 to support a supplemental New Drug Application.
The company is also developing a different formulation of crofelemer for intestinal failure, including microvillous inclusion disease (MVID) and short bowel syndrome, with groundbreaking Phase 2 data showing a 27% reduction in total parenteral support for MVID patients and an upcoming FDA meeting to discuss expedited approval.
Jaguar Health's approved product, Mytesi, for chronic diarrhea in HIV/AIDS patients, is experiencing 5% annual sales growth, and its conditionally approved veterinary product, Canalevia CA1, recently received a $250,000 grant award for its confirmatory trial.
The company is actively pursuing major corporate partnerships to secure non-dilutive funding for its de-risked development programs, targeting significant market opportunities such as the $4.5 billion short bowel syndrome market.

Sep 30, 2025, 7:30 PM

Transcript

Jaguar Health Files for Orphan Drug Designation and Secures Grant

JAGX

New Projects/Investments

Guidance Update

Jaguar Health (JAGX) has filed for Orphan Drug Designation (ODD) with the FDA for metastatic breast cancer, specifically for breast cancer that has metastasized to the brain, a strategy intended to expedite approval and leverage regulatory flexibility.
The company's key asset, crofelemer, is an FDA-approved, plant-based drug with 156 issued patents and no generic pathway, offering significant exclusivity.
Jaguar Health also received a $250,000 grant to support a confirmatory trial for Canalevia, its conditionally approved product for chemotherapy-induced diarrhea in dogs, aiming to maintain market access and potentially expand its indication.
The company is actively pursuing business development deals to secure non-dilutive funding for its late-stage programs, which include cancer therapy-related diarrhea and intestinal failure.

Sep 25, 2025, 6:55 PM

Transcript

Jaguar Health, Inc. completes private placement of Series N Preferred Stock

JAGX

Convertible Preferred Issuance

New Projects/Investments

Jaguar Health, Inc. completed a private placement of approximately 951 shares of Series N Perpetual Preferred Stock, raising approximately $2.38 million.
The private placement closed on September 10, 2025, with proceeds intended for working capital, general corporate purposes, and repayment of certain existing notes.
The Series N Preferred Stock has a stated value of $2,500.00 per share and is exchangeable for Common Stock at an exchange price of $1.20 per share following stockholder approval.
The company is required to hold a stockholder meeting within 90 days of the closing to obtain the necessary approval for the exchange of shares and will file a registration statement on Form S-3 within 30 days for the resale of the exchangeable shares.
Holders of Series N Preferred Stock will not receive any dividends.